Charles Jillings, CEO of Utilico, energized by strong economic momentum across Latin America. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFrontier Ip Regulatory News (FIPP)

Share Price Information for Frontier Ip (FIPP)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 41.50
Bid: 41.00
Ask: 42.00
Change: -2.00 (-4.60%)
Spread: 1.00 (2.439%)
Open: 43.50
High: 43.50
Low: 41.50
Prev. Close: 43.50
FIPP Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Frontier IP to host Portfolio Demo Day

6 Dec 2022 07:00

RNS Number : 6710I
Frontier IP Group plc
06 December 2022
 

Reach - a non-regulatory announcement

AIM: FIPP

06 December 2022

 

Frontier IP Group Plc

("Frontier IP" or the "Group")

 

 

Portfolio news - Frontier IP to host Portfolio Demo Day at the Imperial War Museum, Duxford Cambridge

 

 

Frontier IP, a specialist in commercialising intellectual property, is holding a Portfolio Demo Day at the Imperial War Museum, Duxford, Cambridge ("IWM Duxford" or the "Museum") on the afternoon and evening of Tuesday 6th December 2022.

 

The event is an opportunity for some of Frontier IP's portfolio companies to present, demonstrate and discuss their new technologies to help tackle fundamental challenges, such as climate, energy, food, water and health.

 

Guests include investors, representatives of companies supported by Frontier IP, and industry partners. An afternoon session in the Museum's Marshall Auditorium will consist of presentations from portfolio companies, while the evening reception will give them the opportunity to showcase their technology. No new material information will be disclosed.

 

The portfolio companies presenting and demonstrating technologies are:

 

· Cambridge Raman Imaging is using graphene-based ultra-fast lasers and artificial intelligence in next generation Raman-imaging microscopes to research, diagnose and monitor diseases, such as cancers

 

· CamGraPhIC is developing graphene-based photonics with the potential to make data and telecommunications transmission much faster while using less energy

 

· Elute is showcasing its use of forensic linguistic algorithms for high-speed search and comparison of unstructured document datasets

 

· Celerum is demonstrating its novel artificial intelligence based on meta-heuristics, including nature-inspired computing, to make logistics more efficient, supporting efforts to improve the industry's carbon efficiency

 

· Nandi Proteins is discussing its customised ingredients based on vegetable and animal proteins. These can be used to replace undesirable ingredients such as fat, gluten and E-number additives in processed foods, or those that people do not want to consume - for example replacing animal proteins with vegetable proteins

 

· The Vaccine Group is developing novel herpesvirus-based vaccine platforms. Projects include those to tackle Lassa fever, African Swine Fever, Streptococcus suis and Porcine Reproductive and Respiratory Syndrome in animals, and COVID-19 in humans

 

· Pulsiv will be showing its patented technology to significantly improve the energy efficiency of power supplies, battery chargers, and LED lighting. It also extracts much more energy from photovoltaic solar cells, improving their output

 

· Alusid is creating premium-quality tiles and architectural surfaces from industrial waste.

 

· Des Solutio is developing safer and greener alternatives to the chemicals currently used to make beauty, pharmaceutical, personal healthcare and other products

 

· InSignals Neurotech is showing its patented technology to aid deep brain surgery on patients suffering neurological diseases, such as Parkinson's disease

 

· AquaInSilico is presenting its sophisticated software tools to optimise wastewater treatment, with potential applications spanning many different industries. It is a UN Ocean Innovator, working on a project to help protect and conserve one of the world's most diverse marine environments around the Cape Verde archipelago

 

· Liquid Graphene is a new spin-out company looking to exploit graphene-based inks to reduce the cost of solar cell manufacture and use

 

 

Frontier IP Chief Executive Officer Neil Crabb said: "We are looking forward to demonstrating the exciting technologies being developed by our portfolio companies and the role they have to play in helping to meet some of the serious challenges posed by climate change, water, food and energy."

 

 

 

 

 

 

ENQUIRIES

 

 

Frontier IP Group Plc

T: 020 7332 2338

Neil Crabb, Chief Executive Officer

Andrew Johnson, Communications and investor relations

andrew.johnson@frontierip.co.uk

Company website: www.frontierip.co.uk

neil@frontierip.co.uk

M: 07464 546 025

 

 

Allenby Capital Limited (Nominated Adviser)

Nick Athanas / George Payne

 

 

 

T: 0203 328 5656

 

 

 

 

 

ABOUT FRONTIER IP

Frontier IP unites science and commerce by identifying strong intellectual property and accelerating its development through a range of commercialisation services. A critical part of the Group's work is involving relevant industry partners at an early stage of development to ensure technology meets real world demands and needs.

The Group looks to build and grow a portfolio of equity stakes and licence income by taking an active involvement in spin-out companies, including support for fund raising and collaboration with relevant industry partners at an early stage of development.

About Reach announcements

 

This is a Reach announcement. Reach is an investor communication service aimed at assisting listed and unlisted (including AIM quoted) companies to distribute media only / non-regulatory news releases into the public domain. Information required to be notified under the AIM Rules for Companies, Market Abuse Regulation or other regulation would be disseminated as an RNS regulatory announcement and not on Reach.

 

 

 

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRAVELFBLLLXFBB
Date   Source Headline
17th Apr 20241:59 pmRNSHolding(s) in Company
12th Apr 20247:00 amRNSAppointment of Chief Financial Officer
2nd Apr 202412:44 pmRNSHolding(s) in Company
14th Mar 20247:00 amRNSUnaudited Half Year Results
4th Mar 20241:40 pmRNSHolding(s) in Company
29th Feb 20243:12 pmRNSSale of shares in Exscientia
30th Jan 202411:45 amRNSHolding(s) in Company
22nd Jan 20247:00 amRNSOctopus invest in Alusid as part of equity funding
29th Dec 202312:00 pmRNSTotal Voting Rights
19th Dec 20234:46 pmRNSHolding(s) in Company
15th Dec 20236:12 pmRNSReplacement - Result of AGM and Directorate Change
15th Dec 20232:07 pmRNSResult of AGM and Directorate Change
13th Dec 20237:00 amRNSPortfolio news - The Vaccine Group
11th Dec 20237:00 amRNSHolding(s) in Company
30th Nov 20235:00 pmRNSTotal Voting Rights
30th Nov 20237:00 amRNSExercise of Options & Director/PDMR Shareholdings
28th Nov 20237:00 amRNSBoard Change
21st Nov 20237:00 amRNSPosting of Annual Report and Notice of AGM
9th Nov 20235:27 pmRNSHolding(s) in Company
3rd Nov 20237:05 amRNSGrant of options
1st Nov 20235:48 pmRNSExercise of Options & PDMR Shareholdings & TVR
31st Oct 20237:01 amRNSBoard changes
31st Oct 20237:00 amRNSFinal results for the year ended 30 June 2023
23rd Oct 20237:00 amRNSNew portfolio company Deakin Bio-Hybrid Materials
12th Oct 20232:05 pmRNSHolding(s) in Company
21st Sep 20237:00 amRNSExscientia announces collaboration with Merck
14th Sep 20235:21 pmRNSHolding(s) in Company
14th Sep 20237:00 amRNSExercise of Options & Total Voting Rights
11th Sep 20237:00 amRNSPortfolio news – Pulsiv appoints Chairman and CPO
8th Sep 20237:00 amRNSExercise of Options & Total Voting Rights
10th Aug 20238:45 amRNSPortfolio news – Fieldwork Robotics
24th Jul 20237:00 amRNSPortfolio news – CamGraPhIC loan facility
20th Jul 20235:18 pmRNSHolding(s) in Company
1st Jun 20237:00 amRNSSale of shares in Exscientia
26th May 20236:06 pmRNSHolding(s) in Company
9th May 20237:00 amRNSTopps Tiles launches first Alusid made tile range
21st Apr 20234:00 pmRNSDirectorate Change
20th Apr 20235:26 pmRNSHolding(s) in Company
27th Mar 20235:17 pmRNSHolding(s) in Company
17th Mar 20232:46 pmRNSGrant of options
15th Mar 20237:00 amRNSBoard changes
15th Mar 20237:00 amRNSUnaudited Half Year Results
30th Jan 20237:00 amRNSAlusid in collaboration with Imerys
9th Jan 20237:00 amRNSCelerum appoints David Gladding as CEO
9th Dec 20224:08 pmRNSResult of AGM
7th Dec 20221:25 pmEQSThe Vaccine Group completes two deadly disease vaccination projects
6th Dec 20227:00 amRNSFrontier IP to host Portfolio Demo Day
5th Dec 20227:00 amRNSThe Vaccine Group completes Lassa fever project
2nd Dec 20227:00 amRNSThe Vaccine Group completes vaccine project
30th Nov 20225:00 pmRNSTotal Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.